Journal article
Treatment of thrombosis with fondaparinux (Arixtra) in a patient with end-stage renal disease receiving hemodialysis therapy
Journal of pediatric hematology/oncology, Vol.29(8), pp.581-584
08/01/2007
DOI: 10.1097/MPH.0b013e3181256ba5
PMID: 17762502
Abstract
Treatment of thrombosis in children with end-stage renal disease (ESRD) is extremely challenging owing to the underlying risk of bleeding. Fondaparinux (Arixtra, Sanofi-Synthelabo), a synthetic pentasaccharide, is contraindicated in patients with compromised renal function as it is excreted via kidneys. We describe a unique case with ESRD and pulmonary embolism who was treated with fondaparinux owing to the toxicity and poor compliance with low-molecular-weight heparin. Despite regular hemodialysis, a gradual rise in drug levels was observed without significant bleeding complications. This report implies that although low dose fondaparinux can be an option in patients with ESRD under special circumstances, guidelines for laboratory monitoring and appropriate dose adjustments are urgently required to ensure the safety of the patient.
Details
- Title: Subtitle
- Treatment of thrombosis with fondaparinux (Arixtra) in a patient with end-stage renal disease receiving hemodialysis therapy
- Creators
- Anjali Alatkar Sharathkumar - C. S. Mott Children's HospitalChristina Crandall - University of Michigan–Ann ArborJen-Jar Lin - East Carolina UniversitySteven Pipe - South Australia Pathology
- Resource Type
- Journal article
- Publication Details
- Journal of pediatric hematology/oncology, Vol.29(8), pp.581-584
- Publisher
- Lippincott Williams & Wilkins
- DOI
- 10.1097/MPH.0b013e3181256ba5
- PMID
- 17762502
- ISSN
- 1077-4114
- eISSN
- 1536-3678
- Number of pages
- 4
- Language
- English
- Date published
- 08/01/2007
- Academic Unit
- Stead Family Department of Pediatrics; Hematology/Oncology
- Record Identifier
- 9984353829302771
Metrics
12 Record Views